News | November 07, 2024
RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
The first phase of the Aptivate Achi Bhookh Fest reached over 8,200 households
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
Subscribe To Our Newsletter & Stay Updated
